Evolva CEO exercises options, increases his shareholding in Evolva
Evolva (SIX: EVE) today announces that Neil Goldsmith, CEO of Evolva, has exercised options that he held to acquire 3.8 million new Evolva shares, simultaneously selling 2.2 million of them to cover the acquisition costs and taxes related to the option transaction, leaving him with an additional 1.6 million shares.
As a result of this transaction, Mr Goldsmith’s shareholding in Evolva has more than doubled to around 2.9 million shares, or 0.9% of the company’s share capital. The exercised options stem from a grant in 2009 and had an exercise price of CHF 0.33. The transaction provided CHF 1.2 million in net proceeds to Evolva. The option exercise will also be disclosed via the Swiss Stock Exchange platform for management transactions.
– Ends –
Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.
+ 41 61 485 2005
|Jakob Dynnes Hansen
+ 41 61 485 2034
+ 41 61 485 2035
THIS PRESS RELEASE CONTAINS SPECIFIC FORWARD-LOOKING STATEMENTS, E.G. STATEMENTS INCLUDING TERMS LIKE BELIEVE, ASSUME, EXPECT OR SIMILAR EXPRESSIONS. SUCH FORWARD LOOKING STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY RESULT IN A SUBSTANTIAL DIVERGENCE BETWEEN THE ACTUAL RESULTS, FINANCIAL SITUATION, DEVELOPMENT OR PERFORMANCE OF THE COMPANY AND THOSE EXPLICITLY OR IMPLICITLY PRESUMED IN THESE STATEMENTS. AGAINST THE BACKGROUND OF THESE UNCERTAINTIES READERS SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS OR TO ADAPT THEM TO FUTURE EVENTS OR DEVELOPMENTS.
Stay informed Join our mailing list to receive Evolva’s press releases via e-mail.Join